The first potential approval for simeprevir, and the one we have the most data on, is basically a better interferon-based regimen. I'm not so sure what's so "breakthrough" about that.
The FDA agrees with you—they said no :- )
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”